Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.46 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6568000 | 0.83 | MAPK14 (0.39) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL5457810 | 0.82 | CYP1A2 (0.41) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL5457805 | 0.82 | CYP1A2 (0.41) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL18189934 | 0.80 | MAPK14 (0.42) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL5455918 | 0.74 | CSNK1E (0.41) | MAPK14MAPK10 | |
| SCHEMBL5453011 | 0.73 | MAPK14 (0.56) | MAPK14 | |
| SCHEMBL4478240 | 0.69 | PTGS2 (0.56) | MAPK14 | |
| SCHEMBL5457542 | 0.69 | MAPK14 (0.38) | MAPK14 | |
| SCHEMBL5379439 | 0.68 | MAPK14 (0.54) | MAPK14 | |
| SCHEMBL4488848 | 0.68 | PTGS2 (0.55) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232623-A1 | Pyrazolopyrimidine and Pyrazolotriazine Derivatives and Pharmaceutical Compositions Containing Them | GUDMUNDSSON KRISTJAN | 2007-10-04 | — | — | US | disclosed |
| US-7247626-B2 | Pyrazolopyrimidine derivatives and pharmaceutical compositions containing them | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1485385-B1 | PYRAZOLOPYRIMIDINE AND PYRAZOLOTRIAZINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITHKLINE BEECHAM CORP (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20050124616-A1 | Pyrazolopyrimidine and pyrazolotriazine derivatives and pharmaceutical compositions containing them | SMITHKLINE BEECHAM CORPORATION | 2005-06-09 | — | — | US | disclosed |
| EP-1485385-A1 | PYRAZOLOPYRIMIDINE AND PYRAZOLOTRIAZINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SmithKline Beecham Corporation (US) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003076441-A1 | PYRAZOLOPYRIMIDINE AND PYRAZOLOTRIAZINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITHKLINE BEECHAM CORPORATION (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124616-A1 | Pyrazolopyrimidine and pyrazolotriazine derivatives and pharmaceutical compositions containing them | CYP3A5, CYP3A4, CYP3A7 | MAPK14 2705/4885MAPK13 2770/4885MAPK12 1822/4885 |
| US-20070232623-A1 | Pyrazolopyrimidine and Pyrazolotriazine Derivatives and Pharmaceutical Compositions Containing Them | CYP3A5, CYP3A4, CYP3A7 | MAPK14 2705/4885MAPK13 2770/4885MAPK12 1822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.